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Microneedle devices offer minimally invasive and rapid biomarker extraction from the
skin. However, the lack of effective assessment tools for such microneedle devices
can delay their development into useful clinical applications. Traditionally, the
microneedle performance is evaluated i) in vivo, using animal models, ii) ex vivo,
on excised human or animal skin or iii) in vitro, using homogenised solutions with
the target antigen to model the interstitial fluid. In vivo and ex vivo models are
considered the gold-standard approach for the evaluation of microneedle devices
because of their structural composition, however they do exhibit limitations. More
specifically, they have limited availability and they present batch-to-batch variations
depending on the skin origin. Furthermore, their use rises ethical concerns regarding
compliance with the globally accepted 3Rs principle of reducing the use of animals
for research purposes. At the same time, in vitro models fail to accurately mimic
the structure and the mechanical integrity of the skin tissue that surrounds the
interstitial fluid. In this study, we introduce for the first time an animal-free,
mechanically robust, 3D scaffold that has great potential as an accurate in vitro
evaluation tool for immunodiagnostic microneedle devices. More specifically, we
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demonstrate, for the first time, successful extraction and detection of a melanoma
biomarker (S100B) using immunodiagnostic microneedles in the 3D culture system.
Melanoma cells (A375) were cultured and expanded for 35 days in the highly porous
polymeric scaffold followed by in situ capture of S100B with the microneedle device.
Scanning electron microscopy showed a close resemblance between the 3D scaffold
and human skin in terms of internal structure and porosity. The microneedle
device detected S100B in the scaffold (with a detection pattern similar to the
positive controls), while the biomarker was not detected in the surrounding liquid
supernatants. Our findings demonstrate the great potential of this animal-free 3D
tool for rapid and low-cost evaluation of microneedle devices.
Keywords: Microneedles, diagnostic device, biomarker detection, S100B, melanoma,
three-dimensional in vitro model
Highlights
• A 3D animal-free tool for assessment of immunodiagnostic microneedles is intro-
duced.
• A 3D highly porous structure which mimics the porosity of skin is manufactured.
• S100B detection with microneedles in a novel 3D melanoma culture is evaluated.
1 Introduction
In recent years, a range of solid and hollow microneedles (MNs) have been developed
for dermal drug delivery and diagnostic applications [1–13]. As a dermal diagnostic
device, MNs are advantageous over conventional methods for skin biomarker extraction.
Traditional biomarker extraction techniques necessitate the collection of a significant
volume (several millilitres) of biofluids, and are therefore limited to liquid tissues (e.g.
blood and urine). In this regard, detection of biomarkers on skin, which is a solid tissue,
remains challenging due to lack of efficient sampling and detection methods [14–17].
Instead, invasive skin biopsies have been used routinely, but they cause significant physical
trauma and mental distress to the patient, as well as requiring extensive histological
processing and patient aftercare [16,18–20]. Therefore, MNs offer an attractive alternative
to skin biopsies, as they can penetrate the dermal tissue in a minimally invasive manner,
causing minimal tissue damage and little to no pain [21, 22]. Additionally, MNs can
easily access the interstitial fluid (ISF) that surrounds the tissue cells, making biomarker
capturing in the ISF possible [14]. This is of great importance, especially for the early
detection of malignant diseases, as the cancer biomarker concentration in the tumour
ISF is anticipated to be significantly higher than in the plasma [23].
Current assessment of MNs detection performance is mainly carried out (i) in vivo
using animal models, (ii) ex vivo using excised human or animal skin, or (iii) in vitro
using liquid biomarker solutions [8–12,24].
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In vivo models are not ideal due to ethical, economic and practical reasons. Moreover,
animal-free models are strongly encouraged by the European legislation under the 3R’s
principle of reducing, refining and replacing animal experimentation whenever possible
[25, 26]. Furthermore, excised skin ex vivo models entail their own ethical considerations,
as well as being expensive and limited in availability [27,28]. Excised human skin tumour
samples are especially difficult to obtain for pre-clinical experimentation, as they are used
for disease diagnosis. Among a wide range of animal models that have been suggested
as a replacement for human skin, porcine skin is the most relevant, as it shows striking
histological and biochemical similarities to the human skin [29,30]. Nonetheless, porcine
skin has been reported to exhibit higher permeability than human skin [31–33]. Finally,
the inherent interspecies variations and batch-to-batch variability depending on the skin
origin may complicate the interpretation of experimental results [27,34].
Current in vitro models for microneedle (MN) assessment consist of liquid biomarker
solutions that are used as a surrogate of the skin ISF. These homogenous solutions contain
specific concentrations of the target biomarker to be extracted by the MNs. However,
the homogenous solutions are unable to recapitulate the 3D structure and porosity of
the actual skin tissue, therefore failing to act as accurate skin surrogates. Hence, the
liquid solutions might give a preliminary indication of the detection performance of
the MN devices, but more physiologically relevant evaluation models are needed. More
specifically, to develop realistic models for the assessment of the MNs, it is essential to
mimic the skin tissue properties (i.e. porosity, structure, elasticity, oxygenation level).
Those properties are different for each individual and are influenced by numerous factors,
including, gender, anatomical site, tissue depth, level of hydration and age [35–40]. For
example, the aging skin is characterised by increased stiffness due to the deposition and
fragmentation of collagen [41]. Also, the pore size of the human skin increases with
distance from the skin surface [42]. Although the oxygenation levels in the skin tissue are
difficult to measure accurately, the skin is considered a mildly hypoxic tissue [40, 43, 44].
Therefore, it is important to develop easily tuneable and versatile in vitro skin tools for
MN evaluation, which can easily capture the skin properties.
Three-dimensional (3D) biomaterial-based structures can provide a more realistic
structure/architecture for cells to grow in vitro, enhancing cell-cell spatial interactions
and providing a tissue-specific internal structure. Therefore, such 3D constructs could
be promising tools for the evaluation of MN devices [45–49]. However, to the authors’
knowledge, only one study has explored the potential of a 3D tool for this purpose. Omolu
et al. developed a 3D in vitro tool to test MN rollers for drug delivery purposes [4]. The
in vitro tool consisted of a synthetic membrane placed on the top of collagen gels seeded
with primary fibroblasts. However, the skin structural and mechanical integrity is still
lacking in currently available 3D systems. The use of polymeric foam type scaffolds of
controlled porosity could be a promising approach to recapitulate the human skin internal
structure and stiffness. These scaffolds have tuneable properties (i.e. porosity, stiffness)
to mimic the structural variability of human skin [50]. Additionally, the internal pore
network of these scaffolds provide physical surfaces for the cells to bind and interact with
each other. Importantly, the porous network facilitates nutrient and oxygen diffusion,
thus enabling the long-term culture of the cells in vitro [48–50].
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In this work, we present for the first time, a novel, animal-free, mechanically robust,
versatile 3D polyurethane (PU) scaffold that can be used as a tuneable low-cost tool
for assessing immunodiagnostic MNs able to capture specific biomarkers in the skin.
Metastatic melanoma cells were cultured in the scaffold and S100B, a well-established
intra-tumoural biomarker for cutaneous melanoma [51, 52], was captured in situ with
MNs. Malignant melanoma is the most lethal skin cancer, with a 5-year survival rate of
just 20% [53,54]. The most effective treatment for melanoma is surgical resection, and
early detection greatly enhances prognosis. An elevated serum 100B concentration is
not only associated with malignant melanoma but provides prognostic value as well [55],
which underpins its use as the target biomarker in this study
2 Materials and methods
2.1 Fabrication and characterisation of immunodiagnostic MN devices
Polylactic acid (PLA)-based immunodiagnostic MN devices were fabricated and charac-
terised as described previously [12]. Briefly, PLA (Maker Bot, USA) was melted into
a polydimethylsiloxane micromould at 200°C and 100mbar. The PLA was allowed to
solidify in the micromould following cooling to room temperature. The resultant PLA MN
device was ejected from the micromould and immersed in 6%w/v hexamethylenediamine
(prepared in propan-1-ol) at 50°C for 90 s, followed by immersion in 2%w/w aqueous
glutaraldehyde at room temperature for 3 h to facilitate covalent antibody immobilisation.
The MN devices thus prepared were then washed with deionised water, air-dried, and
coated in a multiplex format with (i) an anti-human S100B monoclonal antibody (clone
8B10, used at 1mg/mL; Bio-Rad, UK), (ii) 5%w/v bovine serum albumin (BSA; prepared
in phosphate buffered saline pH 7.4 with 0.05%w/v Tween® 20) as negative control,
and (iii) horseradish peroxidase (HRP) as positive control. Coating was achieved by
dipping each MN individually into the coating solution 20 times, with 1–2min drying
time in between. Coated MN arrays were immersed in 5%w/v BSA solution, at 4°C for
24 h, to block non-specific binding sites. The coated MNs were then air-dried, ready for
use in biomarker detection experiments. The MN devices were observed under a CETI
Steddy stereomicroscope (Medline Scientific, UK). Images were recorded using a 3Mpx
digital camera (Medline Scientific, UK). Measurements of the MNs were performed on
the images using the ImageJ software version 1.52k (National Institutes of Health, USA),
calibrated against the image of a stage micrometer (Cole-Palmer, USA) at the same
magnification.
2.2 Fabrication and sterilisation of the scaffolds
The PU scaffolds were fabricated by thermally induced phase separation (TIPS), as
previously described [49, 56, 57]. Briefly, PU beads (Noveon, Belgium) were dissolved
in dioxane (5%w/v) (99.8% anhydrous pure, Sigma-Aldrich, UK) and the solution was
quenched at −80°C for 3 h. Thereafter, the solvent was removed by freeze-drying in
an ethylene glycol (EG) bath at −15°C under 0.01 bar vacuum pressure. The scaffolds
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were cut into 5 × 5 × 2.5mm3 cuboids. The thickness of the scaffolds (2.5mm) is a
good representation of the human epidermis and dermis thickness [58–61]. The elastic
modulus of the scaffolds, as evaluated with compression tests, was 33.17± 2.08 kPa. The
elastic modulus of the polymeric scaffolds lies within the elastic properties of the human
skin, which vary significantly depending on the gender, the age and the anatomical
site [60,62]. The average pore size that was measured previously was 100–150µm and
the porosity 85–90% [56]. Sterilisation of the scaffolds took place by washing them with
70%v/v ethanol solution for 3 h, followed by exposure to a UV/ozone generator for 10min
(BioForce Nanosciences, USA).
2.3 3D melanoma cell culture
The human malignant melanoma cell line A375 (Sigma-Aldrich UK, ECAAC 88113005)
was expanded in tissue culture plastic flasks (Fisher Scientific, UK) in Dulbecco’s mod-
ified Eagle’s medium (DMEM) with 4.5 g/L glucose (Lonza, UK), supplemented with
15%v/v heat inactivated foetal bovine serum (FBS; Fisher Scientific, UK), 100U/mL
penicillin/streptomycin (Sigma-Aldrich, UK) and 2mM L-glutamine (Sigma-Aldrich,
UK). Mycoplasma negative cultures were ensured by regular mycoplasma screening tests
(Lonza, UK). 106 cells were seeded in each scaffold. Thereafter, the scaffolds were placed
in 24-well plates and allowed to settle for 30min in an incubator at 37°C in 5% CO2
and 95% air. Afterwards, 1.5mL of the cell culture medium was added in each well and
the scaffolds were kept in an incubator at 37°C, 5% CO2 and 95% air. Cell viability
was evaluated with live/dead staining (section 2.5) on day 5 and 35 of culture. The cell
culture medium was replenished every two to three days. To avoid cell confluency at
the bottom of the wells resulting from cells exiting the scaffolds, samples were placed
in a new well-plate on a weekly basis. Every week, the spent medium from at least two
independent scaffolds was aspirated, centrifuged at 300 × g for 10min to remove any
remaining debris and stored at −20°C for further analysis.
2.4 Scanning electron microscopy
The 3D scaffolds were sectioned and the cell distribution and adhesion on/in the pores
of the matrix was observed with scanning electron microscopy (SEM). The specimens
were collected at the culture endpoint (day 35), snap-frozen in liquid nitrogen for
15min and then preserved in −80°C until fixation. At fixation, samples where sectioned
approximately in the middle with a razor and then directly immersed in 4%v/v cold
formaldehyde solution (Sigma-Aldrich, UK) for 2 h at room temperature. Thereafter,
post fixation took place including 2 washing steps with PBS for 15min each, followed
by 4 washing steps with deionized water for 15min each to ensure removal of the
residual crystals. Afterwards, the scaffold sections were air-dried overnight in an aseptic
environment. The specimens were sputter coated with gold in an argon atmosphere 24 h
prior to the SEM imaging. The SEM was performed on a JEOL 7100F (JEOL USA, MA,
USA) microscope at different magnifications.
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Figure 1: Schematic representation of S100B detection in the 3D melanoma culture with the
immunodiagnostic MN device.
2.5 In situ live/dead staining viability assay
Cell viability in the scaffolds was visualised with confocal laser scanning microscopy
(CLSM). As per section 2.4, scaffolds were collected at the beginning of the culture (day
5) and at the culture end point (day 35), snap-frozen in liquid nitrogen for 15min and
preserved at −80°C. After sectioning, the samples were incubated with calcein AM (2µM;
Life Technologies, Paisley, UK) and ethidium homodimer-1 (4µM; Life Technologies)
in culture medium for 1 h at 37°C. The presence of live (green) and dead (red) cells
was evaluated with a Nikon Ti-Eclipse inverted confocal microscope (Nikon Instruments,
Europe) and processed with Nikon software (Nikon Instruments, Europe).
2.6 Biomarker capture and detection
The immunodiagnostic MN devices were administered on the 3D scaffolds seeded with
melanoma cells on day 35 of culture, ensuring penetration of the specimens, and incubated
in situ for 3 h (Figure 1). Meanwhile, separate MN devices were incubated for 2 h with:
(i) supernatants of the 3D-scaffolded melanocyte culture at the same time point (day
35); (ii) 100µg/mL recombinant human S100B (Abcam, UK) in freshly prepared culture
medium as the positive control; (iii) freshly prepared culture medium without S100B as
negative control. Captured S100B was detected using the blotting method, as previously
described [12]. Briefly, MN devices were washed thoroughly with the wash buffer (PBS
with 0.05%w/v Tween® 20) and incubated with 2µg/mL HRP-conjugated anti-human
S100B detection antibody (clone 6G1; Abcam, UK) for 1 h. Thereafter, the MN devices
were washed thoroughly with the wash buffer again and air-dried. The MN devices were
then placed on chromatography paper wetted with 1.6mg/mL o-phenylenediamine (OPD)
solution (prepared in 50mM phosphate citrate buffer containing 0.03%w/v NaBO3, pH
5.0), ensuring contact between the MN tips and the paper by applying gentle pressure
constantly for 30min. The enzymatic conversion of OPD by HRP (where present) at
points of contact between the MN tips and the OPD-wetted paper would produce a
yellow colouration and a blot pattern corresponding to the positions of the MNs. By
comparing the blot pattern with the coating map, S100B capture was determined.
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2.7 Serum negativity validation
A validation study was performed to verify that any S100B apparently detected by
the MNs had originated from the melanoma cells and not due to cross-reactivity with
unspecified FBS constituents (e.g. bovine S100B) present in the cell culture medium.
Sequence homology between human S100B (GenBank accession no. AAH01766.1) and
bovine S100B (GenBank accession no. ABA39829.1) was analysed using the BLASTp
sequence analysis tool (version 2.8.1; https://blast.ncbi.nlm.nih.gov) [63]. In addition,
a conventional sandwich enzyme-linked immunosorbent assay (ELISA) was performed
using the same assay reagents as those used with the MN device. A 96-well microtitre
plate was first coated with 100µL of the anti-S100B capture antibody (2µg/mL, prepared
in carbonate buffer, pH 9.6) per well, at 4°C overnight. The capture antibody solution
was removed and the wells incubated with the blocking buffer, again at 4°C overnight, to
block non-specific binding sites. The wells were emptied and incubated for 2 h, at room
temperature, with 100µL of serially diluted recombinant S100B solutions in high-glucose
DMEM, with or without 15%v/v FBS. Following thorough washout of the wells with
the wash buffer, 100µL of the HRP-conjugated detection antibody (2µg/mL) was added
to each well and incubated for 1 h. The wells were then thoroughly washed out again
with the wash buffer and incubated with 100µL of the OPD solution for 20–30min. The
absorbance of the OPD solution was measured at 450 nm on a UVM 340 microplate
reader (Asys Hitech, Austria). Data from 5 independent experiments were analysed.
Since each assay varied slightly in terms of reagent incubation time and the rate at which
the colour signal developed from OPD, in collating the results, the normalised signal was
calculated according to Equation 1.
Normalised signal (%)= A−Amin
Amax −Amin × 100 (1)
Where, A is the absorbance of any given sample, whilst Amin and Amax denote the
minimum and maximum absorbance amongst all samples tested in the same experiment,
respectively.
3 Results and discussion
Melanoma is the most lethal skin cancer and the most efficient treatment for it is early
diagnosis followed by surgical resection before metastasis [64]. A MN device that can
detect melanoma biomarkers in the skin easily and rapidly can enable melanoma screening
and early diagnosis at the point of care. In this study, we report for the first time a
reproducible, animal-free, inexpensive scaffolding tool to rapidly assess the detection of
a melanoma biomarker in vitro using a minimally-invasive MN device. To the authors’
knowledge, this is also the first report of a MN device successfully capturing a cancer
biomarker (S100B) from a 3D culture of melanoma cells.
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3.1 Evaluation of 3D melanoma culture performance prior to MN
administration
We have developed a highly porous polyurethane based scaffold which was used as a
basis to grow/expand malignant skin cell lines in 3D [49, 57]. This polymeric scaffold
was chosen because its internal structure and porous configuration (Figure 2 (a)) closely
resemble the human skin (Figure 2 (b)). Additionally, the capability to fine-tune the
scaffold’s mechanical properties (stiffness, elasticity and porosity, by varying known TIPS
parameters) is advantageous for in vitro skin studies, as it enables similar variations in
human skin properties to be simulated [35–39,42].
To evaluate the growth of melanoma cells in the 3D scaffold, 106 melanoma cells
were seeded in the PU matrix and cultured for 35 days. The cell distribution within
the scaffold was evaluated with SEM. The micrographs (Figure 2 (c-d)) indicate that
the A375 cells retained their typical epithelial morphology within the scaffold [65–67].
Additionally, the viability of the 3D melanoma culture remained high for 35 days, as
evaluated by a live/dead viability assay (Figure 2 (e–f)). The cells were distributed
as single cells at the beginning of the culture (Figure 2 (e)), however as the culture
evolved the cells proliferated up to day 35 in the 3D model and formed larger cellular
aggregates (Figure 2 (f)). It is worth noting that 3D in vitro melanoma cultures typically
last for 2 weeks [67–70]. Apart from Hill et al. whose melanoma culture lasted for 35
days, using a 200µm-thick, commercially available polystyrene 3D scaffold, our scaffold
also demonstrated excellent cellular viability and growth characteristics maintenance for
35 days [71, 72]. This enhanced scaffold thickness, as well as the ability to tune it, is
important because tumour thickness increases with disease progression, and even the
earliest stage (T1) cutaneous melanoma can be up to 1mm thick from the epidermal
surface [73]. The thickness of our 3D culture system (2.5mm) corresponds to the invasion
depth of a T3 tumour. It not only provides the ability to mimic the full thickness of
cutaneous melanoma beyond T1, but will also accommodate full insertion of MNs longer
than 200µm.
3.2 S100B capture in the 3D scaffold with MNs
3.2.1 MN device characteristics
Once the high viability of the melanoma cells in the 3D model was confirmed, the
potential to use this system as an in vitro tool for S100B detection with the MN device
was evaluated. The MN devices used in the positive control experiments had 35 MNs per
device, while the rest had 34 MNs per device. These were arranged in 5 rows consisting
of 5, 8, 9/8, 8 and 5 MNs, respectively (Figure 3 (a)). In all cases, the MNs were conical
with a slightly convex surface, approximately 1mm long and 230µm in base diameter.
The coating map of the MNs is presented in Figure 3 (a).
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Figure 2: Evaluation of the 3D melanoma culture. SEM images of (a) the microporous 3D
scaffold without cells; (b) human skin (adapted from Loh and Choong, 2013 [42];
Image used with the permission of the publisher). (c–d) A375 melanocytes in sections
of the scaffold at day 35 of culture. (e–f) Visualization of A375 viability in the scaffold
with fluorescence live (green, calcein AM) and dead (red, ethidium homodimer-1)
viability assay at (e) day 5 of culture and (f) day 35 of culture.
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Figure 3: (a) Coating map of the MN device. S100B detection with the blotting technique
in (b) the 3D scaffold, (c) the 3D melanoma culture supernatants, (d) the positive
control comprising 100µg/mL S100B in fresh culture medium, (e) the negative control
comprising fresh culture medium only. (b–e) Images on the left show the blots adjusted
for brightness and contrast only; images on the right show the corresponding blots
with the blot patterns accentuated using the “Edge Detect” filter in the GNU Image
Manipulation Program (GIMP, version 2.8.18; https://www.gimp.org).
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Figure 4: ELISA calibration plots showing normalised signal (Equation 1) against dilution
factor for DMEM supplemented with FBS and/or S100B. The plots show that FBS
constituents in the cell culture medium did not cross-react with the antibodies used
with MN devices, thus confirming the melanoma cells as the source of the S100B
detected. Data are mean ± standard deviations from 5 independent experiments.
Error bars are staggered for clarity.
3.2.2 In situ S100B capture on the 3D melanoma culture and culture
supernatants
Figure 3 (b) shows the blotting patterns of S100B detection in the scaffold, which
corresponds to the positions of the MNs. The MN device captured S100B from the 3D
melanoma cell culture, producing a clear, visible colour signal similar to the positive
control (Figure 3 (d)). The results show that the MN devices were sensitive and the
S100B detection was specific. To our knowledge, this is the first time that S100B has
been detected by MNs in a 3D biomaterial-based melanoma culture. Considering that
our sequence homology analysis had shown human S100B to be 97% identical and 100%
similar to bovine S100B, we were prompted to investigate potential cross-reactivity
between the antibodies used and FBS, by examining the dose-response relationship
between FBS supplementation and the signal produced in a conventional (plate-based)
ELISA. Our results demonstrate that FBS did not produce a false positive in the assay,
so cross-reactivity can be ruled out (Figure 4). We therefore conclude that the S100B
detected by the MN devices originated from the melanoma cells in the 3D scaffold.
S100B is over-expressed in malignant melanoma and belongs to the S100 protein family.
Dysregulation of the S100 proteins is a characteristic of many cancers [74]. Intra-tumoural
S100B is an established histological marker in the diagnosis of cutaneous melanoma, whilst
elevated serum S100B concentrations are associated with metastatic melanoma, with some
studies reporting prognostic value [75]. However, the S100 proteins are highly conserved
among vertebrates [76–78]. At present, the exact intra-tumoural (interstitial) S100B
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concentration in melanoma is unclear, but inferences may be made from documented
serum concentrations. In melanoma patients, serum S100B concentrations of several
hundred pg/mL have been reported, while for healthy individuals the concentration
range is 20–80 pg/mL [79–81]. Assuming that the elevated serum S100B concentration
originates from the primary tumour, and that the release of S100B from the tumour into
the serum tends towards a concentration equilibrium, then the intra-tumoural S100B
concentration can be estimated to be in the order of at least several hundred pg/mL. A
similar MN device from our laboratory has previously detected a different target antigen
at 10 pg/mL, so a suitable detection limit for intra-tumoural S100B seems achievable
with the MN approach. S100B capture with the MNs was also attempted on the 3D
culture supernatants in order to compare the testing capacity of the 3D model over the
culture spent medium [12]. However, as it is indicated in Figure 3 (c), S100B gradients
were not detected in the 3D scaffold supernatants. This might be attributed to S100B
concentration gradient existence inside of the scaffold and outside. Typically, higher
biomarker concentrations are observed closer to the cells that produce them [23, 82].
Additionally, the presence of the scaffold matrix is likely to have slowed down the diffusion
of the S100B in the culture medium, allowing an even higher concentration gradient
to build up. Nonetheless, the 3D melanoma scaffold is likely to mimic the diffusion
gradients of biomarkers through the skin occurring in vivo, an important feature for MN
assessment [83].
Overall, the findings highlight that our scaffolding tool can be an animal-free, in vitro
tool to test MN devices for diagnostic applications, offering many advantages over other
systems currently in use. More specifically, the scaffold tool: (i) is reproducible without
batch-to-batch variations, (ii) is easily tuneable in terms of their mechanical properties,
internal architecture and porosity to simulate the 3D structure, mechanical properties
and porosity of the human skin (Figure 2 (a–b)), and (iii) can be fabricated at low
cost [35,42,49,56,57,60,84].
4 Conclusions
In this study, a 3D biomaterial-based scaffold was used as an in vitro tool for evaluating
an immunodiagnostic MN device for S100B detection. We have demonstrated, for the
first time, the use of the 3D polyurethane scaffold as an animal-free melanoma surrogate
for screening and evaluating immunodiagnostic microneedles. The 3D scaffold has a
similar internal structure and porosity to human skin. Furthermore, the high tuneability
of the scaffold properties (i.e. porosity, elasticity, biochemical composition, oxygenation
levels etc.) is beneficial in order to recapitulate the in vivo variability in these properties.
Melanoma cells were able to grow in the 3D scaffold for 35 days, the longest yet reported
for in vitro melanoma cell culture. Furthermore, the melanoma marker S100B was
successfully detected using a novel immunodiagnostic MN device on the in vitro tool.
Admittedly, the performance of the MN device may vary depending on various factors,
such as the target protein, the extracellular matrix environment, the assay reagents and
the detection method. Whilst further studies will need to fully assess the performance of
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the MN device for S100B detection, this work has demonstrated the great potential of
the 3D-scaffolding tool in facilitating that process. Overall, our 3D scaffolding tool can
be used as an inexpensive, animal-free, reproducible model for validation/screening of
novel diagnostic devices.
Acknowledgements
This work was supported by the Chemical and Process Engineering Department of the
University of Surrey as well as an Impact Acceleration Grant (IAA-KN9149C) of the
University of Surrey, an IAA–EPSRC Grant (RN0281J) and the Royal Society. It was
also supported by the School of Pharmacy (Newcastle University), School of Pharmacy
and Biomolecular Sciences (University of Brighton), as well as a University of Brighton
Rising Stars Award to KWN.
Biographies
Stella Totti is a postdoctoral researcher at the Department of Chemical and Process
Engineering of the University of Surrey (UK). She received her PhD from the Uni-
versity of Surrey (UK) and her MEng from the Aristotle University of Thessaloniki
(AUTH) in Greece. Her research focuses on cancer tissue engineering, transdermal
delivery of active compounds, biomaterial and nanomaterial development and char-
acterisation, high-throughput (drug and radiotherapy) screening, in situ biomarker
monitoring with advanced imaging techniques.
Keng Wooi Ng is a lecturer at Newcastle University. He received his MPharm and PhD
from Cardiff University (UK), and trained as a postdoctoral researcher at Imperial
College London (UK) and University of Reading (UK). He accepted a lectureship
at University of Brighton (UK) in 2014 and moved to Newcastle University in 2017.
His research focuses on developing novel diagnostic and drug delivery technologies
for the skin. Recent works include microneedle biosensors, nanomedicines and skin
penetration enhancement using chemical penetration enhancers.
Lorraine Dale has a BSc in Cell and Molecular Biology from Kings College London.
She completed her MSc in Biomedical Sciences from University of Brighton in
2017, where she researched a diagnostic microneedle device for melanoma biomarker
detection in the skin, under the supervision of Dr Keng Wooi Ng. She is currently
24quality control and compliance co-ordinator at the Agora fertility clinic in
Brighton, and a visiting researcher at University of Brighton where she continues
to work on immunodetection of melanoma biomarkers.
Guoping Lian has a joint appointment as Science Leader at Unilever R&D Colworth
(80%) and Professor at the Department of Chemical and Process Engineering of
University of Surrey. His main research interest is in multi-scale computational
methods applied to (a) pharmacokinetics of transdermal bioavailability and (b)
13
Accepted Manuscript Totti et al. 2019
complex microstructures, properties and processes of multiphase granules, emulsions
and dispersions.
Tao Chen is a senior lecturer at the University of Surrey. He received his BEng and
MEng from Tsinghua University, China, and PhD from Newcastle University,
UK, and trained as a postdoctoral researcher at Newcastle University. Prior to
joining the University of Surrey in 2011, he had been an assistant professor at
Nanyang Technological University, Singapore. His research focuses on process
systems engineering, developing computational models to help understand and
optimise drug delivery and other chemical and biological processes.
Eirini Velliou is Senior Lecturer (Associate Professor) of Bioprocess & Tissue Engi-
neering, Principal Investigator and Founder of the Bioprocess and Biochemical
Engineering group (BioProChem) in the Department of Chemical and Process 25En-
gineering at the University of Surrey in the United Kingdom. Eirini holds a PhD
from KULeuven, Belgium and an MEng in Chemical Engineering from the National
Technical University of Athens, Greece. Her research focus falls within the engineer-
ing and validation of novel biomaterial based in vitro platforms for studying various
biological systems and diseases, i.e., cancer, stem cells, formulation/communication
of bacterial communities and bacterial-host interactions. Furthermore, she is partic-
ularly interested on the response and adaptation/resistance of biological systems to
environmental stress. Eirini joined the University of Surrey in September 2014 after
postdoctoral appointments at Imperial College London and at the Bioengineering
Group of the Earth and Life Institute (ELI) of the Université Université Catholique
de Louvain (UCL) in Louvain-la-Neuve, Belgium.
References
[1] A. Nayak, D.B. Das, Potential of biodegradable microneedles as a transdermal
delivery vehicle for lidocaine, Biotechnol Lett, 35 (2013) 1351–63.
[2] J. Chen, W. Huang, Z. Huang, S. Liu, Y. Ye, Q. Li, et al., Fabrication of Tip-
Dissolving Microneedles for Transdermal Drug Delivery of Meloxicam, AAPS Pharm-
SciTech, 19 (2018) 1141–51.
[3] E. Larrañeta, S. Stewart, S.J. Fallows, L.L. Birkhäuer, M.T.C. McCrudden, A.D.
Woolfson, et al., A facile system to evaluate in vitro drug release from dissolving
microneedle arrays, Int J Pharm, 497 (2016) 62–9.
[4] A. Omolu, M. Bailly, R.M. Day, Assessment of solid microneedle rollers to enhance
transmembrane delivery of doxycycline and inhibition of MMP activity, Drug Deliv,
24 (2017) 942–51.
[5] S. Liu, M.-n. Jin, Y.-s. Quan, F. Kamiyama, H. Katsumi, T. Sakane, et al., The de-
velopment and characteristics of novel microneedle arrays fabricated from hyaluronic
14
Accepted Manuscript Totti et al. 2019
acid, and their application in the transdermal delivery of insulin, J Control Release,
161 (2012) 933–41.
[6] L.M. Strambini, A. Longo, A. Diligenti, G. Barillaro, A minimally invasive microchip
for transdermal injection/sampling applications, Lab Chip, 12 (2012) 3370–9.
[7] A. Bhargav, D.A. Muller, M.A.F. Kendall, S.R. Corrie, Surface Modifications of
Microprojection Arrays for Improved Biomarker Capture in the Skin of Live Mice,
ACS App Materi Interfaces, 4 (2012) 2483–9.
[8] E. Caffarel-Salvador, A.J. Brady, E. Eltayib, T. Meng, A. Alonso-Vicente, P.
Gonzalez-Vazquez, et al., Hydrogel-Forming Microneedle Arrays Allow Detection of
Drugs and Glucose In Vivo: Potential for Use in Diagnosis and Therapeutic Drug
Monitoring, PLoS One, 10 (2015) e0145644.
[9] J.W. Coffey, S.R. Corrie, M.A. Kendall, Early circulating biomarker detection using
a wearable microprojection array skin patch, Biomaterials, 34 (2013) 9572–83.
[10] K.T. Lee, D.A. Muller, J.W. Coffey, K.J. Robinson, J.S. McCarthy, M.A.F. Kendall,
et al., Capture of the Circulating Plasmodium falciparum Biomarker HRP2 in a
Multiplexed Format via a Wearable Skin Patch, Analyt Chem, 86 (2014) 10474–83.
[11] D.A. Muller, S.R. Corrie, J. Coffey, P.R. Young, M.A. Kendall, Surface Modified
Microprojection Arrays for the Selective Extraction of the Dengue Virus NS1 Protein
As a Marker for Disease, Analyt Chem, 84 (2012) 3262–8.
[12] K.W. Ng, W.M. Lau, A.C. Williams, Towards pain-free diagnosis of skin diseases
through multiplexed microneedles: biomarker extraction and detection using a highly
sensitive blotting method, Drug Deliv Transl Res, 5 (2015) 387–96.
[13] P. Miller, M. Moorman, R. Manginell, C. Ashlee, I. Brener, D. Wheeler, et al.,
Towards an Integrated Microneedle Total Analysis Chip for Protein Detection,
Electroanalysis, 28 (2016) 1305–10.
[14] P.P. Samant, M.R. Prausnitz, Mechanisms of sampling interstitial fluid from skin
using a microneedle patch, Proceedings of the National Academy of Sciences of the
United States of America, 115 (2018) 4583–8.
[15] Y.-C. Kim, J.-H. Park, M.R. Prausnitz, Microneedles for drug and vaccine delivery,
Adv Drug Deliv Rev, 64 (2012) 1547–68.
[16] C. Ericsson, M. Nistér, Protein Extraction from Solid Tissue, in: J. Dillner (Ed.)
Methods in Biobanking, Humana Press, Totowa, NJ, 2011, pp. 307–12.
[17] N.L. Anderson, Counting the proteins in plasma, Clin Chem, 56 (2010) 1775–6
[18] L. Fuertes, C. Santonja, H. Kutzner, L. Requena, Immunohistochemistry in Der-
matopathology: A Review of the Most Commonly Used Antibodies (Part I), Actas
Dermo-Sifiliográficas (English Edition), 104 (2013) 99–127.
15
Accepted Manuscript Totti et al. 2019
[19] L.A. Compton, G.F. Murphy, C.G. Lian, Diagnostic Immunohistochemistry in
Cutaneous Neoplasia: An Update, Dermatopathology, 2 (2015) 15–42.
[20] S.J. Ohsie, G.P. Sarantopoulos, A.J. Cochran, S.W. Binder, Immunohistochemical
characteristics of melanoma, J Cutan Pathol, 35 (2008) 433–44.
[21] M.I. Haq, E. Smith, D.N. John, M. Kalavala, C. Edwards, A. Anstey, et al.,
Clinical administration of microneedles: skin puncture, pain and sensation, Biomed
Microdevices, 11 (2009) 35–47.
[22] J. Gupta, H.S. Gill, S.N. Andrews, M.R. Prausnitz, Kinetics of skin resealing after
insertion of microneedles in human subjects, J Control Release, 154 (2011) 148–55.
[23] S.-M. Ahn, R. J Simpson, Body fluid proteomics: Prospects for biomarker discovery,
Proteomics Clin Appl (2007) 1004–15.
[24] E.M. Vicente-Perez, E. Larrañeta, M.T.C. McCrudden, A. Kissenpfennig, S. Hegarty,
H.O. McCarthy, et al., Repeat application of microneedles does not alter skin
appearance or barrier function and causes no measurable disturbance of serum
biomarkers of infection, inflammation or immunity in mice in vivo, Eur J Pharm
Biopharm, 117 (2017) 400–7.
[25] M.L. Graham, M.J. Prescott, The multifactorial role of the 3Rs in shifting the
harm-benefit analysis in animal models of disease, Eur J Pharmacol, 759 (2015)
19–29.
[26] T. Hartung, Thoughts on limitations of animal models, Parkinsonism Relat Disord,
14 Suppl 2 (2008) S81–3.
[27] E. Abd, S.A. Yousef, M.N. Pastore, K. Telaprolu, Y.H. Mohammed, S. Namjoshi, et
al., Skin models for the testing of transdermal drugs, Clin Pharmacol: advances and
applications, 8 (2016) 163–76.
[28] T. Denayer, T. Stöhr, M. Van Roy, Animal models in translational medicine: Vali-
dation and prediction, New Horizons Transl Med, 2 (2014) 5–11.
[29] B. Godin, E. Touitou, Transdermal skin delivery: predictions for humans from in
vivo, ex vivo and animal models, Adv Drug Deliv Rev, 59 (2007) 1152–61.
[30] U. Jacobi, M. Kaiser, R. Toll, S. Mangelsdorf, H. Audring, N. Otberg, et al., Porcine
ear skin: an in vitro model for human skin, Skin Res Technol, 13 (2007) 19–24.
[31] E.C. Jung, I. Howard, Maibach, Animal Models for Percutaneous Absorption, in:
P.V.P. Shah, I.H. Maibach, J. Jenner (Eds.), Topical drug bioavailability, bioequiva-
lence, and penetration, 2 ed., 2014, New York, 2014.
[32] D. Krajnovic, N. Dragicevic, Ethical Conciderations in Research Involving Dermal
and Transdermal Drug Delivery, in: N. Dragicevic, H.I. Maibach (Eds.), Percutaneous
16
Accepted Manuscript Totti et al. 2019
Penetration Enhancers Drug Penetration Into/Through the Skin, 1 ed., Springer,
Berlin, 2017.
[33] L. Luo, A. Patel, B. Sinko, M. Bell, J. Wibawa, J. Hadgraft, et al., A comparative
study of the in vitro permeation of ibuprofen in mammalian skin, the PAMPA model
and silicone membrane, Int J Pharm, 505 (2016) 14–9.
[34] T.F. Vandamme, Use of rodents as models of human diseases, J of pharmacy &
Bioall Sci, 6 (2014) 2–9.
[35] S. Diridollou, D. Black, J.M. Lagarde, Y. Gall, M. Berson, V. Vabre, et al., Sex- and
site-dependent variations in the thickness and mechanical properties of human skin
in vivo, Int Journal Cosmet Sci, 22 (2000) 421–35.
[36] J. Sandby-Moller, T. Poulsen, H.C. Wulf, Epidermal thickness at different body sites:
relationship to age, gender, pigmentation, blood content, skin type and smoking
habits, Acta Derm Venereol, 83 (2003) 410–3.
[37] H. Tagami, M. Ohi, K. Iwatsuki, Y. Kanamaru, M. Yamada, B. Ichijo, Evaluation
of the skin surface hydration in vivo by electrical measurement, J Invest Dermatol,
75 (1980) 500–7.
[38] C.H. Daly, G.F. Odland, Age-related changes in the mechanical properties of human
skin, J Invest Dermatol, 73 (1979) 84–7.
[39] S. Diridollou, V. Vabre, M. Berson, L. Vaillant, D. Black, J.M. Lagarde, et al., Skin
ageing: changes of physical properties of human skin in vivo, Int Journal Cosmet
Sci, 23 (2001) 353–62.
[40] S.M. Evans, A.E. Schrlau, A.A. Chalian, P. Zhang, C.J. Koch, Oxygen levels in
normal and previously irradiated human skin as assessed by EF5 binding, J Invest
Dermatol, 126 (2006) 2596–606.
[41] J.K. Kular, S. Basu, R.I. Sharma, The extracellular matrix: Structure, composition,
age-related differences, tools for analysis and applications for tissue engineering, J
Tissue Eng, 5 (2014) 2041731414557112.
[42] Q.L. Loh, C. Choong, Three-dimensional scaffolds for tissue engineering applications:
role of porosity and pore size, Tissue Eng Part B, Rev, 19 (2013) 485–502.
[43] B. Bedogni, M.B. Powell, Skin hypoxia: a promoting environmental factor in
melanomagenesis, Cell Cycle, 5 (2006) 1258–61.
[44] B. Bedogni, M.B. Powell, Hypoxia, melanocytes and melanoma - survival and tumor
development in the permissive microenvironment of the skin, Pigment Cell Melanoma
Res, 22 (2009) 166–74.
[45] F.J. O’Brien, Biomaterials & scaffolds for tissue engineering, Mater Today, 14 (2011).
17
Accepted Manuscript Totti et al. 2019
[46] B. Dhandayuthapani, Y. Yoshida, ToruMaekawa, D.S. Kumar, Polymeric Scaffolds
in Tissue Engineering Application: A Review, Int J Polym Sci, 2011 (2011).
[47] E. Burdett, K. Kasper, A.G. Mikos, J.A. Ludwig, Engineering Tumors: A Tissue
Engineering Perspective in Cancer Biology, issue Eng Part B, Rev, 16 (2010) 351–9.
[48] S. Totti, S.I. Vernardis, L. Meira, P.A. Perez-Mancera, E. Costello, W. Greenhalf, et
al., Designing a bio-inspired biomimetic in vitro system for the optimization of ex
vivo studies of pancreatic cancer, Drug Discov Today, 22 (2017) 690–701.
[49] S. Totti, M.C. Allenby, S.B. Dos Santos, A. Mantalaris, E.G. Velliou, A 3D bioinspired
highly porous polymeric scaffolding system for in vitro simulation of pancreatic
ductal adenocarcinoma, RSC Adv, 8 (2018) 20928–40.
[50] A.A. Chaudhari, K. Vig, D.R. Baganizi, R. Sahu, S. Dixit, V. Dennis, et al., Future
Prospects for Scaffolding Methods and Biomaterials in Skin Tissue Engineering: A
Review, Int J Mol Sci, 17 (2016) 1974.
[51] G. Henze, R. Dummer, H.I. Joller-Jemelka, R. Boni, G. Burg, Serum S100--a marker
for disease monitoring in metastatic melanoma, Dermatology (Basel, Switzerland),
194 (1997) 208–12.
[52] H.B. Guo, B. Stoffel-Wagner, T. Bierwirth, J. Mezger, D. Klingmuller, Clinical
significance of serum S100 in metastatic malignant melanoma, Eur J Cancer, 31a
(1995) 1898–902.
[53] R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2018, CA Cancer J Clin, 68
(2018) 7–30.
[54] American Cancer Society, Cancer Facts and Figures 2019, (2019).
[55] R. Harpio, R. Einarsson, S100 proteins as cancer biomarkers with focus on S100B in
malignant melanoma, Clin Biochem, 37 (2004) 512–8.
[56] T.M. Blanco, A. Mantalaris, A. Bismarck, N. Panoskaltsis, The development of a
three-dimensional scaffold for ex vivo biomimicry of human acute myeloid leukaemia,
Biomaterials, 31 (2010) 2243–51.
[57] E.G. Velliou, S.B.D. Santos, M.M. Papathanasiou, M. Fuentes-Gari, R. Misener, N.
Panoskaltsis, et al., Towards unravelling the kinetics of an acute myeloid leukaemia
model system under oxidative and starvation stress: a comparison between two- and
three-dimensional cultures, Bioprocess Biosyst Eng, 38 (2015) 1589–600.
[58] A. Summerfield, F. Meurens, M.E. Ricklin, The immunology of the porcine skin and
its value as a model for human skin, Mol Immunol, 66 (2015) 14–21.
[59] S.H. Bariya, M.C. Gohel, T.A. Mehta, O.P. Sharma, Microneedles: an emerging
transdermal drug delivery system, J Pharm Pharmacol, 64 (2012) 11–29.
18
Accepted Manuscript Totti et al. 2019
[60] H. Joodaki, M.B. Panzer, Skin mechanical properties and modeling: A review, Proc
Inst of Mech Eng H: Journal of Engineering in Medicine, 232 (2018) 323–43.
[61] A.Z. Alkilani, M.T. McCrudden, R.F. Donnelly, Transdermal Drug Delivery: Inno-
vative Pharmaceutical Developments Based on Disruption of the Barrier Properties
of the stratum corneum, Pharmaceutics, 7 (2015) 438–70.
[62] A. Kalra, A.-J. AM, Mechanical Nehaviour of Skin: A Review, J Material Sci Eng,
5 (2016).
[63] S.F. Altschul, T.L. Madden, A.A. Schaffer, J. Zhang, Z. Zhang, W. Miller, et al.,
Gapped BLAST and PSI-BLAST: a new generation of protein database search
programs, Nucleic Acids Res, 25 (1997) 3389–402.
[64] B. Bandarchi, L. Ma, R. Navab, A. Seth, G. Rasty, From melanocyte to metastatic
malignant melanoma, Dermatol Res Pract, 2010 (2010).
[65] S. Avram, D.E. Coricovac, I.Z. Pavel, I. Pinzaru, R. Ghiulai, F. Baderca, et al.,
Standardization of A375 human melanoma models on chicken embryo chorioallantoic
membrane and Balb/c nude mice, Oncol Rep, 38 (2017) 89–99.
[66] A.M. Barsotti, M. Ryskin, W. Zhong, W.G. Zhang, A. Giannakou, C. Loreth, et
al., Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations
promotes aggressive 3D cell morphologies and enhances melanoma tumor growth,
Oncotarget, 6 (2015) 2928–38.
[67] L. Gibot, T. Galbraith, J. Huot, F.A. Auger, Development of a tridimensional
microvascularized human skin substitute to study melanoma biology, Clin Exp
Metastasis, 30 (2013) 83–90.
[68] K. Klimkiewicz, K. Weglarczyk, G. Collet, M. Paprocka, A. Guichard, M. Sarna, et
al., A 3D model of tumour angiogenic microenvironment to monitor hypoxia effects
on cell interactions and cancer stem cell selection, Cancer Lett, 396 (2017) 10–20.
[69] B. Marrero, J.L. Messina, R. Heller, Generation of a tumor spheroid in a microgravity
environment as a 3D model of melanoma, In vitro Cell Dev Biol Anim, 45 (2009)
523–34.
[70] O.F. Kandarakov, M.V. Kalashnikova, A.A. Vartanian, A.V. Belyavsky, Homoge-
neous and heterogeneous in vitro 3D models of melanoma, Mol Biol, 49 (2015)
895–8.
[71] D.S. Hill, N.D.P. Robinson, M.P. Caley, M. Chen, E.A. O’Toole, J.L. Armstrong, et
al., A novel fully-humanised 3D skin equivalent to model early melanoma invasion,
Mol Cancer Ther, 14 (2015) 2665–73.
[72] E. Knight, B. Murray, R. Carnachan, S. Przyborski, Alvetex(R): polystyrene scaffold
technology for routine three dimensional cell culture, Methods in molecular biology
(Clifton, NJ), 695 (2011) 323–40.
19
Accepted Manuscript Totti et al. 2019
[73] C.C. Compton, D.R. Byrd, J. Garcia-Aguilar, S.H. Kurtzman, A. Olawaiye, M.K.
Washington, Melanoma of the Skin, in: C.C. Compton, D.R. Byrd, J. Garcia-Aguilar,
S.H. Kurtzman, A. Olawaiye, M.K. Washington (Eds.), AJCC Cancer Staging Atlas:
A Companion to the Seventh Editions of the AJCC Cancer Staging Manual and
Handbook, Springer New York, New York, NY, 2012, pp. 385–416.
[74] A.R. Bresnick, D.J. Weber, D.B. Zimmer, S100 proteins in cancer, Nat Rev Cancer,
15 (2015) 96.
[75] S. Mocellin, G. Zavagno, D. Nitti, The prognostic value of serum S100B in patients
with cutaneous melanoma: A meta-analysis, Int J Cancer, 123 (2008) 2370–6.
[76] R. Donato, S-100 proteins, Cell calcium, 7 (1986) 123–45.
[77] R. Donato, Perspectives in S-100 protein biology. Review article, Cell calcium, 12
(1991) 713–26.
[78] D.B. Zimmer, E.H. Cornwall, A. Landar, W. Song, The S100 protein family: history,
function, and expression, Brain Res Bull, 37 (1995) 417–29.
[79] A. Díaz-Lagares, E. Alegre, A. Arroyo, M. González-Cao, M.E. Zudaire, S. Viteri,
et al., Evaluation of multiple serum markers in advanced melanoma, Tumor Biol, 32
(2011) 1155.
[80] A. Bolander, M. Agnarsdottir, G. Wagenius, S. Stromberg, F. Ponten, S. Ekman,
et al., Serological and immunohistochemical analysis of S100 and new derivatives
as markers for prognosis in patients with malignant melanoma, Melanoma Res, 18
(2008) 412–9.
[81] K. Müller, A. Elverland, B. Romner, K. Waterloo, B. Langbakk, J. Undén, et al.,
Analysis of protein S-100B in serum: a methodological study, Clin Chem Lab Med
(CCLM) 2011, p. 1111.
[82] H. Haslene-Hox, A. Madani, K.C.G. Berg, K. Woie, H.B. Salvesen, H. Wiig, et
al., Quantification of the concentration gradient of biomarkers between ovarian
carcinoma interstitial fluid and blood, BBA Clinical, 2 (2014) 18–23.
[83] G. Cevc, G. Blume, Lipid vesicles penetrate into intact skin owing to the transdermal
osmotic gradients and hydration force, Biochim Biophys Acta, 1104 (1992) 226–32.
[84] L. Safinia, A. Mantalaris, A. Bismarck, Nondestructive technique for the characteri-
zation of the pore size distribution of soft porous constructs for tissue engineering,
Langmuir, 22 (2006) 3235–42.
20
